COX-2 inhibitors as cancer treatment: will they be the new warfarin or trastuzumab?

Cancer Invest. 2004;22(2):324-5. doi: 10.1081/cnv-120030221.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants / pharmacology
  • Anticoagulants / therapeutic use*
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Clinical Trials as Topic
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Drug Design
  • Humans
  • Neoplasms / drug therapy
  • Trastuzumab
  • Warfarin / pharmacology
  • Warfarin / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Anticoagulants
  • Antineoplastic Agents
  • Cyclooxygenase Inhibitors
  • Warfarin
  • Trastuzumab